Management of Upper Limb Axillo-Subclavian DVT

Initial Assessment and Diagnosis

The American Society of Clinical Oncology recommends confirming diagnosis with venous ultrasound, CT venography with contrast, MR venography with contrast, or x-ray venogram with contrast for patients with suspected upper limb axillo-subclavian DVT 3
Evaluate for potential causes of upper extremity DVT, particularly central venous catheter use, thoracic outlet syndrome, or other anatomical abnormalities, as recommended by the National Comprehensive Cancer Network 3, 1
Assess for risk factors that may influence treatment decisions, including renal function, liver function, pregnancy status, and bleeding risk, as suggested by the American Society of Hematology 4, 1

The American College of Chest Physicians recommends immediate anticoagulation with a direct oral anticoagulant (DOAC) for a minimum of 3 months for patients with upper limb axillo-subclavian DVT 1, 2
The International Society on Thrombosis and Haemostasis suggests that DOACs, such as apixaban or rivaroxaban, are first-line therapy for patients with upper limb axillo-subclavian DVT 4, 1
Alternative options, such as low molecular weight heparin (LMWH) or vitamin K antagonists (VKAs), may be considered if DOACs are contraindicated, as recommended by the American College of Chest Physicians 1, 2

Most patients with upper extremity DVT can be safely treated as outpatients, according to the American Society of Clinical Oncology 1
The American College of Chest Physicians recommends considering hospitalization if the patient has severe symptoms, high bleeding risk, significant comorbidities, or inadequate home support 4
The minimum duration of anticoagulation for unprovoked upper limb DVT is 3 months, as suggested by the International Society on Thrombosis and Haemostasis 2, 5, 1

For patients on DOACs, no routine coagulation monitoring is required, but follow-up at 1 month is recommended to assess symptom improvement and medication adherence, as suggested by the American Society of Clinical Oncology 1
For patients on VKAs, regular INR monitoring is necessary to maintain a target range of 2.0-3.0, as recommended by the American College of Chest Physicians 1, 2
Evaluate for resolution of symptoms and development of post-thrombotic syndrome, as suggested by the International Society on Thrombosis and Haemostasis 5, 1